vs
Side-by-side financial comparison of HANMI FINANCIAL CORP (HAFC) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
HANMI FINANCIAL CORP is the larger business by last-quarter revenue ($71.2M vs $38.3M, roughly 1.9× ImmunityBio, Inc.). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs -161.8%, a 191.6% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 17.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $-71.3M).
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
HAFC vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.2M | $38.3M |
| Net Profit | $21.2M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | 29.8% | -169.0% |
| Net Margin | 29.8% | -161.8% |
| Revenue YoY | 17.1% | 407.0% |
| Net Profit YoY | 20.0% | -4.7% |
| EPS (diluted) | $0.70 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.2M | $38.3M | ||
| Q3 25 | $71.0M | $32.1M | ||
| Q2 25 | $65.2M | $26.4M | ||
| Q1 25 | $62.8M | $16.5M | ||
| Q4 24 | $60.8M | $7.6M | ||
| Q3 24 | $58.5M | $6.1M | ||
| Q2 24 | $56.7M | — | ||
| Q1 24 | $58.4M | — |
| Q4 25 | $21.2M | $-61.9M | ||
| Q3 25 | $22.1M | $-67.3M | ||
| Q2 25 | $15.1M | $-92.6M | ||
| Q1 25 | $17.7M | $-129.6M | ||
| Q4 24 | $17.7M | $-59.2M | ||
| Q3 24 | $14.9M | $-85.7M | ||
| Q2 24 | $14.5M | — | ||
| Q1 24 | $15.2M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 29.8% | -169.0% | ||
| Q3 25 | 31.1% | -173.5% | ||
| Q2 25 | 23.2% | -269.8% | ||
| Q1 25 | 28.1% | -390.1% | ||
| Q4 24 | 29.1% | -919.0% | ||
| Q3 24 | 25.5% | -1314.3% | ||
| Q2 24 | 25.5% | — | ||
| Q1 24 | 26.0% | — |
| Q4 25 | 29.8% | -161.8% | ||
| Q3 25 | 31.1% | -209.8% | ||
| Q2 25 | 23.2% | -350.3% | ||
| Q1 25 | 28.1% | -784.9% | ||
| Q4 24 | 29.1% | -783.4% | ||
| Q3 24 | 25.5% | -1404.0% | ||
| Q2 24 | 25.5% | — | ||
| Q1 24 | 26.0% | — |
| Q4 25 | $0.70 | $-0.06 | ||
| Q3 25 | $0.73 | $-0.07 | ||
| Q2 25 | $0.50 | $-0.10 | ||
| Q1 25 | $0.58 | $-0.15 | ||
| Q4 24 | $0.58 | $-0.08 | ||
| Q3 24 | $0.49 | $-0.14 | ||
| Q2 24 | $0.48 | — | ||
| Q1 24 | $0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $796.4M | $-500.5M |
| Total Assets | $7.9B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $242.8M | ||
| Q3 25 | — | $257.8M | ||
| Q2 25 | — | $153.7M | ||
| Q1 25 | — | $61.6M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $130.4M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $796.4M | $-500.5M | ||
| Q3 25 | $779.5M | $-524.3M | ||
| Q2 25 | $762.8M | $-570.7M | ||
| Q1 25 | $751.5M | $-591.4M | ||
| Q4 24 | $732.2M | $-489.1M | ||
| Q3 24 | $736.7M | $-745.1M | ||
| Q2 24 | $707.1M | — | ||
| Q1 24 | $703.1M | — |
| Q4 25 | $7.9B | $501.9M | ||
| Q3 25 | $7.9B | $519.0M | ||
| Q2 25 | $7.9B | $402.1M | ||
| Q1 25 | $7.7B | $303.8M | ||
| Q4 24 | $7.7B | $382.9M | ||
| Q3 24 | $7.7B | $364.6M | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $7.5B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $206.0M | $-70.4M |
| Free Cash FlowOCF − Capex | $203.7M | $-71.3M |
| FCF MarginFCF / Revenue | 286.2% | -186.2% |
| Capex IntensityCapex / Revenue | 3.2% | 2.4% |
| Cash ConversionOCF / Net Profit | 9.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | $356.1M | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $206.0M | $-70.4M | ||
| Q3 25 | $146.9M | $-68.9M | ||
| Q2 25 | $-19.0M | $-79.7M | ||
| Q1 25 | $25.8M | $-85.9M | ||
| Q4 24 | $52.6M | $-85.1M | ||
| Q3 24 | $6.7M | $-98.8M | ||
| Q2 24 | $2.1M | — | ||
| Q1 24 | $30.0M | — |
| Q4 25 | $203.7M | $-71.3M | ||
| Q3 25 | $146.4M | $-69.6M | ||
| Q2 25 | $-19.6M | $-80.8M | ||
| Q1 25 | $25.6M | $-87.0M | ||
| Q4 24 | $49.9M | $-87.3M | ||
| Q3 24 | $6.5M | $-101.6M | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $29.2M | — |
| Q4 25 | 286.2% | -186.2% | ||
| Q3 25 | 206.3% | -217.2% | ||
| Q2 25 | -30.0% | -305.9% | ||
| Q1 25 | 40.7% | -526.9% | ||
| Q4 24 | 82.1% | -1155.4% | ||
| Q3 24 | 11.1% | -1663.2% | ||
| Q2 24 | 2.3% | — | ||
| Q1 24 | 50.0% | — |
| Q4 25 | 3.2% | 2.4% | ||
| Q3 25 | 0.8% | 2.3% | ||
| Q2 25 | 0.9% | 4.1% | ||
| Q1 25 | 0.4% | 6.8% | ||
| Q4 24 | 4.3% | 28.0% | ||
| Q3 24 | 0.4% | 45.7% | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 9.70× | — | ||
| Q3 25 | 6.66× | — | ||
| Q2 25 | -1.26× | — | ||
| Q1 25 | 1.46× | — | ||
| Q4 24 | 2.97× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 1.98× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
